Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

13/02/2019
Download PDF File (395 Ko)

THERANEXUS set to receive €6.2 million in funding from the French Investments for the
Future program, managed by Bpifrance, for the development of Neurolead,
its new lead generation platform targeting neuro-glia interactions

29/01/2019
Download PDF File

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
13/12/2018
Download PDF File (370 Ko)

Theranexus September 30th cash position and business update
09/11/2018
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

29/10/2018
Download PDF File (371 Ko)

December, 2019 : CF&B Midcap Event, Geneva (exact date to be confirmed)

October 14 & 15, 2019 : CF&B European MidCap Event, Paris

September 20, 2019 : CF&B Midcap Event, Amsterdam

June 18 & 19, 2019 : CF&B Spring European Midcap, Paris 

May 14 & 15, 2019 : Large & MidCap Event (Midcap partners), Paris

April 16 & 17, 2019 : CF&B SmallCap Event, Paris 

April 9 & 10, 2019 : Midcap Event Portzamparc, Paris

April 4 2019: Market Solutions Forum by ESN, Paris